From the Research
Taking Lexapro (escitalopram), Humira (adalimumab), and Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) together requires careful monitoring by healthcare providers due to potential interactions and contraindications. These medications can interact with each other, particularly Lexapro and Biktarvy, which may increase the risk of QT interval prolongation (a heart rhythm abnormality) 1. Additionally, Humira suppresses the immune system, which could potentially interact with Biktarvy's management of HIV infection. Patients taking this combination should watch for signs of serotonin syndrome (confusion, rapid heart rate, high blood pressure, dilated pupils, muscle rigidity), increased infection risk, or heart rhythm changes. Some key points to consider when taking these medications together include:
- Regular monitoring of liver function is important as all three medications can affect the liver 2.
- Never stop or adjust these medications without medical supervision, and always inform all treating physicians about your complete medication list.
- The specific risks depend on individual factors including your medical conditions, dosages, and treatment duration, so personalized medical advice is essential 3.
- Recent studies have shown that Biktarvy is a safe and effective treatment for HIV infection, with high effectiveness and persistence observed among a broad range of people with HIV 1.
- However, the combination of Lexapro, Humira, and Biktarvy has not been specifically studied, and therefore, caution is advised when prescribing this combination 4. It is essential to weigh the benefits and risks of this combination and consider alternative treatments if necessary, prioritizing the patient's morbidity, mortality, and quality of life as the primary outcome 5.